
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 31 |
| Chemical drugs | 2 |
Target |
Mechanism PRPF19 inhibitors |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date01 Jan 1981 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism JMJD1C modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date18 May 2026 |
Sponsor / Collaborator |
Start Date16 Apr 2026 |
Sponsor / Collaborator |
Start Date30 Mar 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
HW-N2001 | Gastroesophageal Reflux More | Phase 1 |
LJ-LD ( Lipid ) | disorder of aging More | Preclinical |
MY-1 | Acute Lung Injury More | Preclinical |
CP-TBA derivatives 17e(Shandong Second Medical University) ( HBV capsid ) | Hepatitis B More | Preclinical |
Compound B3(Shandong Second Medical University) ( PARP1 x PARP7 ) | Neoplasms More | Preclinical |





